Addex Therapeutics Ltd (ADXN) - Net Assets
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has net assets worth CHF5.96 Million CHF (≈ $7.53 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF7.33 Million ≈ $9.27 Million USD) and total liabilities (CHF1.37 Million ≈ $1.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Addex Therapeutics Ltd (ADXN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF5.96 Million |
| % of Total Assets | 81.28% |
| Annual Growth Rate | -7.87% |
| 5-Year Change | -33.81% |
| 10-Year Change | 481.1% |
| Growth Volatility | 671.21 |
Addex Therapeutics Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Addex Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Addex Therapeutics Ltd (ADXN) total assets for the complete picture of this company's asset base.
Annual Net Assets for Addex Therapeutics Ltd (2006–2024)
The table below shows the annual net assets of Addex Therapeutics Ltd from 2006 to 2024. For live valuation and market cap data, see Addex Therapeutics Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF9.67 Million ≈ $12.23 Million |
+744.27% |
| 2023-12-31 | CHF1.15 Million ≈ $1.45 Million |
-76.68% |
| 2022-12-31 | CHF4.91 Million ≈ $6.21 Million |
-70.98% |
| 2021-12-31 | CHF16.93 Million ≈ $21.41 Million |
+15.89% |
| 2020-12-31 | CHF14.61 Million ≈ $18.47 Million |
-42.76% |
| 2019-12-31 | CHF25.52 Million ≈ $32.27 Million |
-34.96% |
| 2018-12-31 | CHF39.24 Million ≈ $49.61 Million |
+2822.90% |
| 2017-12-31 | CHF1.34 Million ≈ $1.70 Million |
+514.17% |
| 2016-12-31 | CHF218.59K ≈ $276.36K |
-86.87% |
| 2015-12-31 | CHF1.66 Million ≈ $2.10 Million |
-29.05% |
| 2014-12-31 | CHF2.35 Million ≈ $2.97 Million |
-22.48% |
| 2013-12-31 | CHF3.03 Million ≈ $3.83 Million |
-81.43% |
| 2012-12-31 | CHF16.29 Million ≈ $20.60 Million |
-51.85% |
| 2011-12-31 | CHF33.84 Million ≈ $42.78 Million |
-47.47% |
| 2010-12-31 | CHF64.41 Million ≈ $81.44 Million |
-16.97% |
| 2009-12-31 | CHF77.58 Million ≈ $98.08 Million |
-34.80% |
| 2008-12-31 | CHF118.99 Million ≈ $150.44 Million |
-15.07% |
| 2007-12-31 | CHF140.11 Million ≈ $177.13 Million |
+231.40% |
| 2006-12-31 | CHF42.28 Million ≈ $53.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Addex Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28892296500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF1.84 Million | 19.06% |
| Other Comprehensive Income | CHF95.68 Million | 989.41% |
| Other Components | CHF265.51 Million | 2745.45% |
| Total Equity | CHF9.67 Million | 100.00% |
Addex Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Addex Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sego Resources Inc
V:SGZ
|
$7.10 Million |
|
Industrial Minerals Ltd
AU:IND
|
$7.10 Million |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
$7.11 Million |
|
Nakoda Group of Industries Limited
NSE:NGIL
|
$7.11 Million |
|
PharmaCyte Biotech Inc
NASDAQ:PMCB
|
$7.09 Million |
|
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc
LSE:ATR
|
$7.09 Million |
|
SCC Holdings Bhd
KLSE:0158
|
$7.09 Million |
|
Tri-Mode System M Bhd
KLSE:0199
|
$7.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Addex Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,145,465 to 9,670,775, a change of 8,525,310 (744.3%).
- Net income of 7,055,787 contributed positively to equity growth.
- Share repurchases of 24,020 reduced equity.
- New share issuances of 240,899 increased equity.
- Other comprehensive income increased equity by 1,248,181.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF7.06 Million | +72.96% |
| Share Repurchases | CHF24.02K | -0.25% |
| Share Issuances | CHF240.90K | +2.49% |
| Other Comprehensive Income | CHF1.25 Million | +12.91% |
| Other Changes | CHF4.46K | +0.05% |
| Total Change | CHF- | 744.27% |
Book Value vs Market Value Analysis
This analysis compares Addex Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.50x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CHF8.43 | CHF0.05 | x |
| 2007-12-31 | CHF27.93 | CHF0.05 | x |
| 2008-12-31 | CHF20.74 | CHF0.05 | x |
| 2009-12-31 | CHF13.53 | CHF0.05 | x |
| 2010-12-31 | CHF10.89 | CHF0.05 | x |
| 2011-12-31 | CHF4.55 | CHF0.05 | x |
| 2012-12-31 | CHF2.06 | CHF0.05 | x |
| 2013-12-31 | CHF0.33 | CHF0.05 | x |
| 2014-12-31 | CHF0.23 | CHF0.05 | x |
| 2015-12-31 | CHF0.15 | CHF0.05 | x |
| 2016-12-31 | CHF0.02 | CHF0.05 | x |
| 2017-12-31 | CHF0.10 | CHF0.05 | x |
| 2018-12-31 | CHF1.68 | CHF0.05 | x |
| 2019-12-31 | CHF0.97 | CHF0.05 | x |
| 2020-12-31 | CHF0.55 | CHF0.05 | x |
| 2021-12-31 | CHF0.50 | CHF0.05 | x |
| 2022-12-31 | CHF0.11 | CHF0.05 | x |
| 2023-12-31 | CHF0.02 | CHF0.05 | x |
| 2024-12-31 | CHF0.10 | CHF0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Addex Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 72.96%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1720.75%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.10x
- Recent ROE (72.96%) is above the historical average (-234.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -48.60% | -433.53% | 0.10x | 1.10x | CHF-24.77 Million |
| 2007 | -25.04% | -7205.50% | 0.00x | 1.07x | CHF-49.10 Million |
| 2008 | -18.54% | -82.32% | 0.20x | 1.11x | CHF-33.97 Million |
| 2009 | -55.03% | -1043.62% | 0.05x | 1.14x | CHF-50.45 Million |
| 2010 | -52.23% | -1703.33% | 0.03x | 1.15x | CHF-40.09 Million |
| 2011 | -92.04% | -1102.95% | 0.06x | 1.29x | CHF-34.52 Million |
| 2012 | -165.85% | -22313.20% | 0.01x | 1.33x | CHF-28.65 Million |
| 2013 | -477.92% | -15760.49% | 0.02x | 1.94x | CHF-14.76 Million |
| 2014 | -75.66% | -2078.19% | 0.02x | 1.70x | CHF-2.01 Million |
| 2015 | -252.62% | -10432.03% | 0.01x | 1.74x | CHF-4.37 Million |
| 2016 | -1440.76% | -18174.08% | 0.01x | 7.70x | CHF-3.17 Million |
| 2017 | -244.35% | -656.22% | 0.16x | 2.28x | CHF-3.41 Million |
| 2018 | -4.19% | -27.21% | 0.14x | 1.08x | CHF-5.57 Million |
| 2019 | -57.91% | -534.98% | 0.08x | 1.29x | CHF-17.33 Million |
| 2020 | -88.01% | -355.92% | 0.18x | 1.38x | CHF-14.32 Million |
| 2021 | -91.05% | -528.58% | 0.13x | 1.33x | CHF-17.11 Million |
| 2022 | -423.46% | -1462.57% | 0.17x | 1.69x | CHF-21.30 Million |
| 2023 | -921.57% | -654.47% | 0.35x | 4.05x | CHF-10.67 Million |
| 2024 | 72.96% | 1720.75% | 0.04x | 1.10x | CHF6.09 Million |
Industry Comparison
This section compares Addex Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $152,067,895
- Average return on equity (ROE) among peers: -28.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Addex Therapeutics Ltd (ADXN) | CHF5.96 Million | -48.60% | 0.23x | $7.10 Million |
| BB Biotech AG (BION) | $1.91 Billion | 10.59% | 0.00x | $2.25 Billion |
| Basilea Pharmaceutica AG (BSLN) | $125.38 Million | -47.04% | 0.20x | $699.48 Million |
| Evolva Holding SA (EVE) | $21.86 Million | -39.62% | 1.03x | $7.08 Million |
| Idorsia Ltd (IDIA) | $-1.21 Billion | 0.00% | 0.00x | $759.27 Million |
| Molecular Partners AG (MOLN) | $135.79 Million | -13.71% | 0.36x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $29.28 Million | -80.19% | 0.42x | $360.88 Million |
| Relief Therapeutics Holding AG (RLF) | $14.30 Million | -52.18% | 0.39x | $36.33 Million |
| Santhera Pharmaceuticals Holding AG (SANN) | $104.47 Million | -42.74% | 0.08x | $244.59 Million |
| Xlife Sciences AG (XLS) | $235.23 Million | 6.08% | 1.08x | $122.27 Million |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more